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Background: Ablation of long-standing persistent atrial fibrillation (AF) is highly variable 
with differing techniques and outcomes.    
Objective: To undertake a systematic review of the literature with regards to the impact of 
ablation technique on the outcomes of long-standing persistent AF ablation. 
Methods: A systematic search (Database: PubMed) of the contemporary English scientific 
literature (1st Jan 1990 to 1st June 2009) was performed and identified 32 studies on 
persistent/long-standing persistent or long-standing persistent AF ablation (including four 
randomized controlled trials). Single procedure-drug free, multiple procedure and 
pharmaceutically assisted success at longest follow-up were collated. 
Results: Four studies performed pulmonary vein isolation alone (PVI; 21-22% success). Four 
studies performed PV antrum ablation with (PVAI; n=2; 38-40% success) or without 
confirmed isolation (PVA; n=2; 37-56% success). Ten studies performed linear ablation (LIN) 
in addition to PVA (n=5; 11-74% success) or PVAI (n=5; 38-57% success). Three studies 
performed posterior wall box isolation (n=3; 44-50% success). Five studies performed 
complex fractionated atrial electrogram (CFAE) ablation (n=5; 24-63% success).  Six studies 
performed CFAE ablation as an adjunct to PVA (n=2; 50-51% success), PVAI (n=3; 36-61% 
success) or PVAI and linear (n=1; 68% success) ablation. Five studies performed the stepwise 
ablation approach (38-62% success). 
Conclusion: The variation in success, within and between techniques, suggests that the 
optimal ablation technique for long-standing persistent AF is unclear. Nevertheless, long-
standing persistent AF can be effectively treated with a composite of extensive index catheter 








AF=atrial fibrillation  
PVI=Pulmonary vein isolation 
PVA=Pulmonary vein antrum 
PVAI=Pulmonary vein antrum isolation 
LIN=Linear ablation  




The success of catheter ablation in  paroxysmal AF patients is now well established1. 
However, when the same approaches are applied to persistent or long-standing persistent AF 
patients, the clinical success has been limited2, 3 and has led to the search for the ideal ablation 
strategy. The vast contrast in success suggests that the mechanisms underlying the 
maintenance of persistent AF are different to their paroxysmal counterparts. These alternative 
mechanisms are perhaps partly related to the significant remodeling that the arrhythmia instills 
on the atria in terms of its structural and electrophysiological properties. Linear lesions and/or 
electrogram-guided atrial substrate modification, targeted at interrupting self-sustaining 
macro- or micro-reentrant wavefronts, or focal sources have been variably incorporated into 
the ablation treatment for persistent/long-standing persistent AF in an attempt to improve 
outcomes. In order to collate the efficacy and complications of current approaches utilized for 
long-standing persistent AF ablation we performed a systematic literature review.  
 
METHODOLOGY FOR REVIEWING THE LITERATURE 
The English scientific literature was searched in Pubmed using: “atrial AND 
fibrillation AND ablation AND (persistent OR long-standing persistent OR chronic OR long-
term OR long-standing)” in any region of the Pubmed record up until the 1st of June 2009. 
Circulation: Arrhythmia and Electrophysiology Journal was manually searched due to its 
limited indexation in Pubmed.  The resultant 1286 abstracts were reviewed to ensure that a 1) 
long-standing persistent or 2) a mixed persistent/long-standing persistent AF cohort 
undergoing radiofrequency catheter ablation for the treatment of their arrhythmia were 
included. Manuscripts reporting on a pure persistent, mixed paroxysmal/persistent or pure 
paroxysmal cohort were excluded.  138 relevant full-text references were examined for a 
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description of baseline characteristics, procedural details, follow-up, complications, and 
success rates for the group or sub-group of interest. Figure 1 shows the number and reason for 
the exclusion of studies from the original retrieved articles. Randomized controlled trials (n=4) 
were reviewed separately, but data were also included in the case-series review to improve 
estimate of success for each ablation strategy. Thirty-two manuscripts met the inclusion 
criteria and a summary of their results are presented in Table 1.  
This review summarizes outcome data from reports on persistent/long-standing 
persistent ablation outcomes. There is potential for sample redundancy; however, we have 
assumed all data are independent in the case series review.  Single procedure, drug-free 
success rate was used as the gold standard comparison criterion. However, multiple procedure 
and pharmaceutically assisted clinical outcomes are also reported. The following definitions 
were used: 
1) Pulmonary vein isolation (PVI):  Ostial ablation of all pulmonary veins with 
confirmation of electrical block.  
2) Pulmonary vein antral (PVA) ablation:  Predominately antral anatomical ablation 
around the pulmonary veins, with an endpoint of on-line voltage abatement and a 
circumferential lesion set.  
3) PVA isolation (PVAI):  PVA with electrical disconnection of the encircled veins 
within the ablated margins. 
 
EVIDENCE FROM RANDOMISED CONTROLLED TRIALS 
Four randomised controlled trials (Level II evidence) examining various ablation 
approaches for long-standing persistent AF have been conducted recently4-7. Unfortunately, 
there is little overlap in the ablation approaches assessed by each study so their data cannot be 
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combined (Figure 2). With respect to the clinical endpoint of single procedure drug free 
success, these studies showed for long-standing persistent: 
1) PVAI is a superior approach compared to PVA ablation alone7. 
2) CFAE ablation alone is an inferior strategy compared to PVA+linear ablation at the 
roof and mitral isthmus. 
3) There is no incremental benefit of additional right atrial CFAE ablation5  when AF 
persisted after left atrial CFAE ablation. 
4) CFAE ablation may7 or may not4 provide incremental benefit when added to PVAI.   
 
PVAI 
A five-centre randomised study, with appropriate web-based permuted block 
randomisation protocol reported that PVAI is an essential component of long-standing 
persistent AF ablation7 (Figure 2), which is consistent with recommendations in the most 
recent ablation guidelines8.  
 
CFAE Ablation alone 
An appropriately randomised (sealed envelopes with treatment assignment) single 
centre study compared left atrial CFAE ablation to conventional pulmonary vein and linear 
ablation6. Three to five left atrial CFAE sites were ablated along the roof, septum, anterior 
wall, mitral isthmus and atrial aspect of the mitral annulus with voltage abatement as an 
endpoint. In the other arm, PVA was performed with lines across the posterior (or roof) and 
mitral isthmus but without confirmation of block or isolation. The empirical approach was 
associated with improved outcomes (Figure 2); however, the 24% increase in radiofrequency 
8 
 
energy delivery time prevented delineation of technique or debulking as the mediator of 
success.   
 
CFAE as an adjunct to PVAI 
Two randomised controlled trials have assessed whether the addition of CFAE ablation 
to PVAI improves clinical results, with conflicting results4,7 (Figure 2). The 5 centre study of 
Elayi et al.7 reported a 61% drug free clinical success in their bi-atrial CFAE+PVAI arm, 
compared to 40% in their PVAI in patients with >1 year of continuous long-standing persistent 
AF. In CFAE+PVAI arm, a much greater proportion of patients terminated to SR or atrial 
tachycardia during PVAI after CFAE ablation (74%) compared to those who received PVAI 
alone (44%), even though only 2% of these patients actually terminated during CFAE 
ablation. In contrast, a single centre study of Oral and colleagues4 selected their long-standing 
persistent cohort as those patients with episodes >6 months, but only randomised patients who 
were non-responsive to PVAI (still inducible or remaining in AF) to either no other ablation 
and/or CFAE ablation of the left atrium and coronary sinus. Even though the latter group 
received a 38% increase in ablation due to targeting of CFAE and acute termination occurred 
in 18% (9/50) of patients during CFAE ablation, the clinical success at a mean follow-up of 
9±4 months was the same as those who received no additional ablation. The primary 
differences between these two conflicting studies include 1) patient characteristics (>1 year vs. 
>6 months), 2) patient selection (unselected versus resistant to PVAI), 3) bi-atrial vs. left atrial 
CFAE ablation and 4) the order in which PVAI/CFAE targeting was performed. It is possible 
that some of these differences may have resulted in the contrasting comparison. The benefits 





EVIDENCE FOR EACH STRATEGY 
Randomised controlled trials have answered some of the questions regarding ablation 
of long-standing persistent AF; however, the critical question of technique over debulking still 
persists. We reviewed the case series (Level IV evidence) to further investigate the outcomes 
associated with the different AF ablation strategies not assessed in randomised comparisons.  
 
PULMONARY VEIN ABLATION 
Pulmonary vein isolation 
In one of the initial descriptions of persistent AF ablation 9, Haissaguerre and 
colleagues described a 40% single procedure drug free success at 11 months after ablation in a 
highly selected group of patients in whom high frequency triggers observed following 
cardioversion of AF were targeted by PVI; however, this sample was not representative of a 
clinical long-standing persistent cohort and the data are therefore excluded from summary.    
Four studies have reported clinical success of PVI in ‘unselected’ persistent or long-
standing persistent disease10-13. The single procedure, drug-free success rates of between 21 
and 22% for three of these studies are consistent with contemporary theory and randomized 
controlled trials2, 3 demonstrating that targeting triggers in chronically diseased and  remodeled 
atria has little clinical effect. The outlying efficacy data of Razavi et al.11 (54% success at 30 
months) should be interpreted with caution as the term ‘symptomatically free’ was used to 
define their success rate, indicating that asymptomatic episodes were not included. Hence, the 
spuriously high success reported by Razavi et al.11  has been excluded from further summary.  
PVI is associated with a single procedure, drug-free success ranging from 21-22% at 
almost two years (Table 2). The integration of repeat procedures (mean 1.6/patient) increases 
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the drug-free success to 37-43%. A combination of drug administration and repeat procedures 
further increased the success rates to ~54% (Table 1). 
 
PVA ablation with and without isolation 
 In the four studies that performed antral encirclement, the majority confirmed PV 
disconnection4, 7, 14. These studies reported superior, but variant (37-56%) single procedure 
success rates compared to PVI alone (Table 1 and Figure 3). The large variation in success 
could be due to fact that Pappone and colleagues15 defined long-standing persistent AF as that 
>3 months compared to Cheema et al.14, who enrolled patients with  >6 months of continuous 
AF.  The mean LA dimension of 58±11 mm in the latter study was also consistent with a more 
severely diseased cohort, and hence, the lowest clinical success. 
Wide vein encirclement is associated with a single procedure, drug free success 
ranging from 37-56% at ~1 year (Table 3). The integration of repeat procedures (mean 
1.3/patient) increases the drug free success to 59%. The combination of drugs and multiple 
procedures yielded a success rate of ~77% (Table 1 and Figure 3). 
 
LINEAR ABLATION  
Linear ablation eliminates more atrial substrate and partially compartmentalizes the 
atria aimed at preventing the formation of macro-reentrant circuits that have been postulated to 
maintain AF. Such linear ablation is anchored to electrically inert structures and has included 
the roofline, mitral isthmus, anterior line and isolation of the entire posterior left atrium.  
 
Linear substrate ablation as an adjunct to pulmonary vein ablation 
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PVA/PVAI plus linear ablation, in the form of roof, mitral isthmus and tricuspid 
isthmus lines is the most common ablation approach in this review. It is important to note that 
a complete set of linear lesions may not be performed in all patients, with procedures often 
tailored to the patient’s response to ablation.   
Ten studies have reported on the clinical success of linear substrate ablation in addition 
to PVA ablation with and without PVI7, 16-23. Gaita et al.18 reported one of the poorest single 
procedure, drug free success rates of only 15% in their long-standing persistent sub-group; 
however, all patients suffered from hypertrophic cardiomyopathy and their results were 
therefore excluded from summary statistics. Similarly, the data of Siedl et al.20 have also been 
excluded as their technique utilized two paired but chronologically-separate procedures of 
linear ablation that is not consistent with contemporary ablation approaches.  
Table 4 demonstrates the chronological transition from PVA encirclement to PVAI 
being used in conjunction with conventional linear lesions. Four studies using PVA in 
conjunction with linear substrate modification6, 7, 19, 21 reported a wide range of success from 
11-74% in comparison to 48-57% for studies utilizing PVAI + linear ablation17, 23. The highly 
variable success rate demonstrates that this approach can produce significantly different 
outcomes in the hands of different operators, perhaps contributed to by differing procedural 
endpoints or the criteria for linear lesion contiguity.  
PVA (or PVAI) with linear substrate modification is associated with a single 
procedure, drug-free clinical success ranging from 11-74% at ~1.5 years (Table 4). The 
integration of repeat procedures (mean 1.5/patient) improved success rates to 17-74% (Table 
1 and Figure 3). The addition of anti-arrhythmics further increased success to 28-87%.  
 
Posterior wall isolation 
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Posterior wall isolation incorporates PVI together with the remaining posterior wall 
tissue. This has been described enbloc or by performing circumferential PVI followed by 
superior and inferior linear ablation to join left and right encirclement.  
Three studies have assessed the efficacy of posterior wall isolation in 2724, 1025, and 24 
long-standing persistent AF 26 patients with >0.5-1 year of continuous AF. Sanders et al.24 
reported a 44% single procedure, drug free success at 23±3 months for posterior wall isolation 
in patients with >6 months of continuous AF. Chen et al.25 described the effectiveness of 
complete posterior wall isolation by combining roofline and inferior left atrial linear lesions to 
pulmonary vein isolation lesion sets. Isolation was confirmed by an inability to capture the 
atrium with posterior wall pacing. The baseline characteristics were reported for the group as a 
whole (n=42; 18 paroxysmal/24 long-standing persistent) and thus cannot be reported here. 
The success rate reported was 50% for single procedure and 60% for a mean of 1.5 procedures 
at an overall follow-up of 20±4 months (Table 5). Kumagai et al26 reported similar results to 
those of the initial description of the ablation approach24 by isolating the posterior wall guided 
by the Ensite non-contact mapping system.  
Posterior wall isolation is associated with a single procedure, drug free success 
ranging from 42-50% at almost two years (Table 5). The integration of repeat procedures 
(mean 1.4/patient) increases the drug free success to 60-63% (Table 1 and Figure 3). The 
incremental efficacy gain with drug administration was increased to 88% in one small sample. 
 
ELECTROGRAM BASED ABLATION  
The clinical outcomes associated with the above procedures suggest that regions other 
than the PVs, PVA and posterior wall may play a role in the maintenance of long-standing 
persistent AF.  In contrast to linear ablation, where a pre-determined linear lesion is created 
13 
 
empirically without detailed consideration of the underlying atrial substrate, electrogram-
guided substrate modification selectively targets atrial tissue dependent upon the electrogram 
characteristics at the site. Electrograms can be targeted in a subjective (physician 
interpretation) or objective (online CFAE detection algorithms) manner.  
 
CFAE ablation alone 
Four studies have utilized CFAE ablation alone in persistent/long-standing persistent 
AF in a total of 270 patients4, 6, 27, 28. It is important to note that signals were not objectively 
characterized using 3D mapping and signal detection algorithms, but instead subjectively 
assessed by the respective operators. Nademanee et al.28 were the first to purport the success 
of pure CFAE ablation but their results have not been reproduced4, 6, 27.  Reasons for this may 
include: operator experience, total ablation time differences, the subjectivity of what 
represented an ‘important’ electrogram and finally, the severity of disease in the cohort. The 
cohort defined as chronic in Nademanee’s study28 consisted of a 40/60 split of persistent (AF 
not terminating in 7 days) and long-standing persistent patients. In addition, left atrial 
dimensions and other baseline characteristics were not detailed. Nevertheless, they reported a 
single procedure, drug free success of 63% at 12 months, which improved to 77% with repeat 
procedures in 19 of the 64 patients (Table 1). A 71% multiple-procedure success rate in 235 
long-standing persistent AF patients was also reported recently by these investigators29; 
however, this study was excluded from the review due to insufficient information about the 
long-standing persistent AF sub-group.   
Oral and colleagues have attempted CFAE ablation in three separate long-standing 
persistent AF cohorts (AF ≥6 months); twice in the setting of a randomized ablation trial4, 6 
and once in a 100 patient series27. The single procedure drug free clinical success ranged from 
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24-33% for these studies with a mean follow-up of 1 to 1.4 years. The only patients that 
performed well in Oral’s randomized controlled trial were the 22% that terminated with left 
atrial CFAE ablation who had an overall single procedure success of 74%4; a finding that is 
consistent across most ablation techniques. In a 100 patient series27, a mean 1.5 procedures per 
patient was associated with a final clinical success of 57% (Table 1). Even in the context of 
shorter ablation times (35-44 minutes), the success rate of CFAE ablation alone therefore 
seems inferior to other empirical techniques, which is supported by the single centre 
randomized controlled trial of Oral et al. 6.  
CFAE ablation alone is associated with a single procedure, drug free success ranging 
from 24-63% at ~1 year (Table 6). The integration of repeat procedures (mean 1.4/patient) 
increases the drug free success to 52-77% (Table 1 and Figure 3). The incremental efficacy 
gain with drug administration and multiple procedures was not reported. 
 
CFAE as an adjunct to conventional approaches  
 Recently, CFAE ablation has been performed as an adjunct to pulmonary vein 
isolation30, 31, PVAI4, 7, 32 or PVAI, roof and mitral isthmus ablation33. Schmitt et al.30  reported 
the outcomes of a 5.5 hour procedure beginning with subjectively-assessed CFAE ablation at 
various regions of the left and right atrium and coronary sinus ostium, followed by 
conventional pulmonary vein isolation. Unfortunately, the authors failed to report the follow-
up frequency, or what was defined as failure or success; however, they reported a 50% success 
rate (intention-to-treat analysis) at 12±3 months follow-up. It is unclear as to whether there is 
cohort redundancy, but the same investigators reported a similar clinical result for 35 
persistent/long-standing persistent AF patients with a follow-up including objective 7 day 
Holter monitoring 31.  
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The highest efficacy reported by Porter and colleagues33 was associated with one of the 
first attempts to objectively quantify (CARTO; Biosense Webster) and target CFAE in 
addition to conventional ablation. The algorithms yielded primary CFAE sites in an average 
24% of the atrium, which were accordingly ablated. In addition to primary CFAE ablation, 
PVAI, roof and mitral isthmus lines were deployed. In their follow-up of all long-standing 
persistent (median AF duration 13 months) patients >1 yr, with Holter monitoring and one 
month of trans-telephonic monitoring at 6 months, they reported a 68% (17/25) single 
procedure, drug free clinical success. Although the objective characterization of CFAE could 
be a contributing factor to the success, equally, this study was the only one to perform roof 
and mitral isthmus linear lesions in addition to PVAI and CFAE.  
Oral and colleagues4, whose group have had little clinical success with CFAE ablation 
alone, reported that the addition of CFAE to PVAI resulted in an equally poor success rate 
compared to PVAI alone and contributed the lowest single procedure, drug free success rate in 
this category (36%). On the other hand, Elayi and colleagues7, who compared the same two 
techniques, found that PVAI and CFAE resulted in a clinical success rate similar (61%) to the 
other case series in this ablation category and that this approach was superior to PVAI alone.     
   Pulmonary vein isolation and CFAE ablation is associated with a single procedure, 
drug-free clinical success of 36-68% at one year (Table 7). Multiple procedures increased the 
success to between 60-80% at the same follow-up. Objective targeting of CFAEs via 
automated algorithms in addition to PVAI and linear ablation may improve clinical outcomes 
but this is yet to be tested in a randomized comparison.   
 
STEPWISE ABLATION APPROACH 
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The stepwise ablation approach is an integration of most of the aforementioned 
techniques in a bid to additively improve the success of persistent/long-standing persistent AF 
ablation. The stepwise approach requires several key ablation techniques, namely: PVI, linear 
ablation at the roof and mitral isthmus, electrogram-targeted ablation and discretionary right 
atrial ablation (SVC, intercaval or CTI lines). Each region is targeted in sequence with the 
effect of ablation assessed by measurement of the AF cycle length. Another important feature 
of the stepwise approach is that the procedure endpoint is dictated by the termination of AF to 
sinus rhythm or intermediate atrial tachycardias; thus minimizing ablation for maximal impact. 
Patients in AF after all key anatomical regions are ablated may be cardioverted at the end of 
the procedure.   
Five studies have reported the clinical success associated with the stepwise ablation 
approach for persistent/long-standing persistent AF34-38. Haissiguerre and colleagues described 
the stepwise ablation approach in 60 persistent/long-standing persistent AF patients with 
regards to critical structures for acute AF slowing or termination and long term clinical 
outcome38. These patients had AF for a mean of 17 months, ranging from one month to 
fourteen years, with 11% being uncardiovertable. The single procedure, drug free success of 
this strategy was 62% at 11±6 months. Allowing for repeated procedures in almost 50% of 
patients the success rate increased to 88% (Table 1 and Figure 3).  
The outcomes of the stepwise ablation approach have also been reported in three 
additional patient series from the same group34, 35, 37. Sacher et al.37 enrolled 43 
persistent/long-standing persistent AF patients (AF mean 11 months, ranging from 1 month to 
6 years) who underwent the same extensive ablation procedure. They reported a longer mean 
follow-up of 18±5 months and a mean of 1.4 procedures yielded a drug free clinical success of 
70% (Table 1). Takahashi et al.34 characterized the electrograms associated with procedural 
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termination of chronic AF and in doing so reported the clinical success (mean follow-up of 
14±3 months) of 40 consecutive patients undergoing the Stepwise ablation technique. The 
single procedure, drug free success in this cohort was 55% (Table 8). The integration of repeat 
procedures for atrial tachycardia (mean 1.4 procedures) yielded an 83% success rate (Table 1). 
The largest and most recent case series of 153 patients35 demonstrated that the stepwise 
ablation approach was associated with a single procedure clinical success of 48%, with anti-
arrhythmic medication and multiple procedures increasing this to 89%. Taken together, these 
studies demonstrate a variance of 48 to 62% with a single procedure from a single centre with 
a well established ablation protocol and potential sample redundancy.  
Rostock et al.36 is the only group outside of Bordeaux to report on the stepwise 
procedure in 88 consecutive persistent/long-standing persistent AF patients (AF duration range 
3-264 months). In this series, the stepwise approach was associated with lower single 
procedure drug free success rate of 38% at 20 months which improved to 81% with the 
integration of repeat procedures. These results may have been due to a more severely diseased 
cohort represented by a higher proportion of structural heart disease (64%), significantly 
enlarged left atria compared to the other studies in this category and the lower rate of AF 
termination during the procedure.  
The stepwise ablation approach is associated with single procedure, drug-free clinical 
success ranging from 38-62 % at ~18 months (Table 8). The integration of repeat procedures, 
mostly for focal atrial tachycardia and flutter, increases the drug free clinical success to 70-
88% and finally, the allowance of previously ineffective anti-arrhythmic drug treatment in the 
patient cohort can further improve clinical success to 84-90% (Table 1 and Figure 3). 
 
SAFETY ASSOCIATED WITH LONG-STANDING PERSISTENT AF ABLATION 
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Assessment of complications was not a primary aim of this review; hence, case reports 
were not included. This may lead to potential underestimation of very rare complications such 
as atrio-esophageal fistula. Twenty-eight of the 32 studies reported peri-procedural 
complications; however, six of these reported complications from their mixed AF type cohort 
and are not summarized here. Complications are reported as a percentage of the total 1690 
patients (n=22 studies) included in the safety review. A total of 75 complications were 
reported (4.4%) which included (in descending prevalence): 23 pericardial 
tamponades/effusions (1.4%), 13 vascular complications (0.80%), 12 symptomatic pulmonary 
vein stenoses (0.71%), 11 cerebrovascular events (0.65%), 7 delayed left atrial appendage 
(LAA) emptying or temporary electrical disconnection of atria or LAA (0.41%), 5 phrenic 
nerve injuries (0.3%) and single cases of atrioesophageal fistula (0.06% each), AV block, 
pulmonary edema, ST segment elevation and severe back pain and no procedurally related 
death.  
The complication data were too limited and variable to infer any relationship between 
ablation approach and risk of procedure.    
 
LIMITATIONS 
 Only two studies7, 26 in this review clearly stated that all of their patients had 
continuous AF >12 months, which is the most recent classification of long-standing persistent 
AF8. All studies referring to their patient cohorts as chronic, persistent/long-standing 
persistent, or long-lasting persistent, but with enrollment criteria deviating from the 
contemporary definition, were included. While the inclusion of these studies allowed for a 
more stable estimate of the efficacy of various substrate ablation approaches, which was the 
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primary aim of this article, it may have an impact on the efficacy estimates provided in this 
review. 
 The most recent guidelines for AF ablation8 recommend a minimum objective follow-
up for at least 12 months in all patients. Only two studies in this review objectively reported 
this statistic19, 33.  Another four other studies7, 13, 24, 28 have presumably followed all of their 
patients for at least 12 months given their mean and standard deviation; albeit none of these 
objectively stated this fact. The impact of including studies which have shorter and variable 
follow-up periods may ultimately overestimate the clinical success for periods greater than 12 
months post index ablation procedure. 
 
CONCLUSION  
This systematic review collates the success associated with long-standing persistent AF 
ablation, with a review of randomized controlled trials and an indirect comparison of case-
series with different baseline characteristics, treated using a variety of methodologies and 
followed up with different intensities. The variation in ablation methodology reported in this 
review demonstrates that the optimal technique for long-standing persistent AF ablation is still 
the subject of robust debate and clinician preference. 
The role of CFAE targeted ablation in long-standing persistent AF is a topic of hot 
debate and has been addressed by several randomized controlled trials. Randomized controlled 
comparisons suggest that CFAE ablation alone is an inferior strategy for the treatment of long-
standing persistent AF compared to empirical approaches 6 and that confirmed electrical 
isolation of PVs (PVAI) is a pivotal component of the latter technique to maximize clinical 
success7. The role of CFAE targeted ablation as an effective adjunct to PVAI remains 
undecided with two randomized controlled trials reporting opposing results 4, 7.    
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Single procedure, drug free clinical success associated with case series data suggests 
that, with the exception of PVI alone (mean 21%) and CFAE ablation alone (mean 37%), all 
contemporary substrate ablation techniques for persistent/long-standing persistent AF provide 
comparable clinical results (mean 47% success; Table 1 and Figure 3).  
Comparisons between contemporary ablation approaches for multiple procedure and 
anti-arrhythmic drug assisted are restricted because of the confounder of how many patients 
received an additional ablation or drugs to maintain sinus rhythm and when these interventions 
occurred during follow-up.  However, it is clear that the clinical outcomes of contemporary 
ablation approaches overall, are significantly improved with repeat procedures (1.4 
procedures; mean 65% success) and/or previously ineffective pharmaceuticals (mean 79% 
success) compared to the mean single procedure drug free clinical success (47%).  Repeat 
procedures and previously ineffective anti-arrhythmic drugs are therefore a critical component 
of current ablation strategies long-standing persistent AF. 
As we continue to understand more about the persistent fibrillatory process, the 
evolution of more specific ablation techniques will hopefully improve efficacy and safety, and 
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Figure 1: The search criteria and a flow diagram of the literature excluded from the original retrieved 
abstracts and full-text articles.   
 
Figure 2:  Single procedure, drug free clinical success associated with ablation approaches for 
persistent/long-standing persistent AF assessed in four randomized controlled trials. 
PVA=pulmonary vein antrum ablation; PVAI=pulmonary vein antrum isolation; 
LIN=conventional linear ablation; CFAE=complex fractionated electrogram ablation. 
 
Figure 3:  Clinical success of various ablation techniques for persistent/long-standing persistent AF. The 
success rate is presented for a single procedure and drug-free success (white), multiple procedure 
(diagonal cross hatch) and AAD-assisted success rates (dark double hatch). Error bars represent ± 
1 SD; bars are absent when estimate is based on one study. PVI=pulmonary vein isolation; 
PVA=pulmonary vein antrum ablation; PVAI=pulmonary vein antrum isolation; 
LIN=conventional linear ablation; BOX=posterior wall isolation; CFAE=complex fractionated 
electrogram ablation; STEPWISE=Stepwise ablation technique. 
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